[发展总体生存预后模型 核心结合因子急性髓性白血病的成年患者]
Lu-Yao Shi1, Ling-Ling Li1, Tao Li1
1Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China.
Zhongguo shi yan xue ye xue za zhi
|June 27, 2024
概括
这项研究确定了关键因素,如年龄,爆发数,AML1-ETO融合基因和KIT突变,这些突变会影响核心结合因子急性髓性白血病 (CBF-AML) 患者的存活率. 一个新的预测模型有助于评估整体存活率 (OS),以便更好地做出治疗决策.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 核心结合因子急性髓性白血病 (CBF-AML) 是AML的一个独特的亚型.
- 确定预后因素对于优化CBF-AML治疗策略至关重要.
- 现有的预测模型可能需要对成年CBF-AML患者进行改进.
研究的目的:
- 确定影响成年CBF-AML患者整体存活期 (OS) 的临床因素.
- 在这个患者队列中开发和验证OS的预测模型.
- 在CBF-AML管理中提供一个信息处理决策的工具.
主要方法:
- 对216名新诊断成年CBF-AML患者的回顾性分析.
- 数据分为培训 (70%) 和验证 (30%) 队列.
- 考克斯回归和逐步回归用于模型开发;ROC,校准和DCA曲线用于性能评估.
主要成果:
- 确定了OS的独立不良预后因素:年龄 (≥55岁),外周血液血清 (≥80%),AML1-ETO融合基因和KIT突变.
- 开发的预测模型表现良好,3年AUC为0.772 (培训) 和0.722 (验证).
- 校准曲线显示预测值和观察值之间的良好一致性;决策曲线分析表明与单个因素相比,性能优越.
结论:
- 已经建立了一个简单且可行的预测模型,用于成年CBF-AML患者的OS.
- 该模型有效预测整体存活率,有助于个性化治疗策略.
- 该工具可以作为CBF-AML临床决策的有价值的基础.
相关概念视频
01:15Differentiation of Common Myeloid Progenitor Cells
3.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.2K
01:21Cancer Survival Analysis
342
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
342
02:07Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K